ToddAdamGerstenMD

Clinical Trials

• LGX818 for Patients With BRAFV600 Mutated Tumors Start of enrollment: 2014 Jan 14

  Terminated

  Phase 2

• A Study of LY3023414 and Necitumumab in Squamous Lung Cancer Start of enrollment: 2015 Jul 01

  Terminated

  Phase 2

• Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Etoposide and Carboplatin in Extensive Stage Small Cell Lung Cancer (SCLC) Start of enrollment: 2015 Jun 26

  Completed

  Phase 1, Phase 2

• Trilaciclib (G1T28) in Patients With Previously Treated Extensive Stage SCLC Receiving Topotecan Chemotherapy Start of enrollment: 2015 Oct 05

  Terminated

  Phase 1, Phase 2

• A Study of Napabucasin (BBI-608) in Combination With FOLFIRI in Adult Patients With Previously Treated Metastatic Colorectal Cancer Start of enrollment: 2016 Jun 01

  Completed

  Phase 3

• Atezolizumab and Tiragolumab in Patients With NSCLC or Advanced Solid Tumors Having Had Prior Treatment With a PD-1 Inhibitor Start of enrollment: 2019 Aug 30

  Active, not recruiting

  Phase 2

• NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC Start of enrollment: 2021 Nov 03

  Active, not recruiting

  Phase 2

  Roles: Contact, Principal Investigator

• Join now to see all